Mosaic ImmunoEngineering Inc.
For the period ended Dec 31, 2025. Filed Apr 15, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Apr 15, 2026
CPMVStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating expenses: | ||
| Research and development | $63,981 | $183,867 |
| General and administrative | 552,138 | 695,788 |
| Total operating expenses | 616,119 | 879,655 |
| Loss from operations | (616,119) | (879,655) |
| Other income (expense): | ||
| Other income | 14,000 | 42,000 |
| Interest income | 6 | 5 |
| Interest expense on loan payable | (10,001) | (6,954 |
| Non-cash interest expense on convertible notes | (73,332) | (73,533) |
| Accretion to redemption value on convertible notes | – | (1,446) |
| Total other income, net | (69,327) | (39,928 |
| Loss before provision for income taxes | (685,446) | (919,583) |
| Provision for income taxes | 2,400 | 2,400 |
| Net loss | $(687,846) | $(921,983) |
| Basic loss per common share | $(0.10) | $(0.13) |
| Diluted loss per common share | $(0.10) | $(0.13) |
| Weighted average number of common shares outstanding – basic | 7,236,447 | 7,236,447 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.